Discover the latest advancements in breast cancer treatment at the 24th Annual International Congress, featuring expert insights and groundbreaking research.

FDA approves tafasitamab with lenalidomide and rituximab, offering a groundbreaking chemotherapy-free treatment for relapsed ...

Recent studies reveal promising outcomes for discontinuing TKI therapy in select patients with Philadelphia ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Panelists discuss how to approach a 67-year-old man with advanced polycythemia vera who is resistant to hydroxyurea, ...

Despite major advances, real-world data show diminishing survival outcomes and treatment-limiting toxicities in second line ...

A recent trial reveals that nivolumab combined with chemotherapy significantly improves survival rates in older patients with ...

Surbhi Sidana, MD, discusses updates from the CARTITUDE-4 study assessing the CAR T therapy cilta-cel in patients with ...

Discover how data analytics transforms health care by reducing costs, improving patient outcomes, and enhancing operational ...

New combination therapy of relacorilant and nab-paclitaxel shows promise in extending survival for patients with ...

During a live event, Jeffrey V. Matous, MD, discussed flexible dosing and the need to expand use in community practices for ...

Detalimogene voraplasmid gains FDA RMAT designation, showcasing a 71% response rate in treating high-risk, BCG-unresponsive ...